Heart Attack (Myocardial Infarction) News and Research

RSS

A Heart Attack (Myocardial Infarction) occurs when blood flow to a section of heart muscle becomes blocked. If the flow of blood isn’t restored quickly, the section of heart muscle becomes damaged from lack of oxygen and begins to die.

Heart attack is a leading killer of both men and women in the United States. But fortunately, today there are excellent treatments for heart attack that can save lives and prevent disabilities. Treatment is most effective when started within 1 hour of the beginning of symptoms. Heart attacks occur most often as a result of a condition called coronary artery disease (CAD). In CAD, a fatty material called plaque (plak) builds up over many years on the inside walls of the coronary arteries (the arteries that supply blood and oxygen to your heart). Eventually, an area of plaque can rupture, causing a blood clot to form on the surface of the plaque. If the clot becomes large enough, it can mostly or completely block the flow of oxygen-rich blood to the part of the heart muscle fed by the artery.

An encouraging decline in heart failure admission numbers: Study

According to heartening news from researchers, hospitalizations for heart failure have dropped 29.5 percent nationally over the past decade. Researchers explain that this is largely because fewer patients were admitted rather than fewer admissions per patient, researchers found.

20 Oct 2011

Raw fruits and veggies may offset genetic risk for heart disease: Study

In a new study a team of researchers looked at the genotypes of 27,243 people from two separate studies to see if they had a certain gene variant. Earlier studies including a 2010 meta-analysis in the Journal of the American Medical Assn. found that the 9p21 gene is associated with a higher risk of heart attack and cardiovascular disease.

13 Oct 2011

Over 13,000 youth to receive cardiac screenings in Oct.

During National Sudden Cardiac Arrest Awareness (SCA) Month in October, thirteen organizations from across the nation are participating in Screen Across America, a national initiative that provides cardiac screenings to youth ages 5-24. The goal of this collaborative effort is to increase awareness about Sudden Cardiac Arrest in youth and the importance of cardiac screenings and early detection in saving young lives.

3 Oct 2011

Study helps predict which ARVD patients are at highest risk of sudden cardiac death

...

22 Sep 2011

Traffic fumes can raise risk for heart attack for at least six hours: Study

According to British researchers breathing in heavy traffic fumes can trigger a heart attack. Heart attack risk is raised for about six hours post-exposure and goes down again after that, researchers found. They say in the British Medical Journal that pollution probably hastens rather than directly cause attacks. But repeated exposure is still bad for health, they say, substantially shortening life expectancy, and so the advice to people remains the same - avoid as far as is possible.

22 Sep 2011

Synthon announces European approvals for Eplerenone

Synthon has successfully concluded multiple registration procedures for the cardiovascular drug Eplerenone. Synthon has obtained regulatory clearance for the product in nine European countries, for both 25 and 50 mg film coated tablets.

15 Sep 2011

Data on veterans affairs hospitals shows high rates of readmissions

The Veterans Health Administration, the largest integrated health care system in the country, has long employed many of the approaches Medicare is pushing on all hospitals to reduce unnecessary readmissions. But new data show VA hospital patients are just as likely to end up back in a hospital bed as are patients at private hospitals.

13 Sep 2011

Australia’s Mesoblast receives nod to start first European trial of allogeneic stem cell treatment for heart attacks

Global regenerative medicine company, Mesoblast Limited, (ASX: MSB), today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor™ in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack. Revascor™ is an allogeneic, or “off-the-shelf”, adult stem cell product derived from Mesoblast's proprietary Mesenchymal Precursor Cell (MPC) platform technology which is being developed for use in a range of cardiovascular diseases including congestive heart failure, chronic angina, and heart attacks (acute myocardial infarction).

5 Sep 2011

Longer CPR may do more harm than good: Study

A new study reveals that providing CPR (cardiopulmonary resuscitation) for a longer period of time could actually harm certain patients. “We found that extra CPR didn't help and, in fact, in some patients it was not a good thing. It would make it worse,” said Dr. Ian Stiell, lead author of a paper published in the Sept. 1 issue of the New England Journal of Medicine. “Our study showed that there's no reason to do two minutes of CPR or to delay defibrillation.”

31 Aug 2011

Foods that can reduce cholesterol

At present those with cholesterol are prescribed cholesterol lowering drugs like statins and a diet that cuts out foods high in saturated fat. New research shows that some foods may help to lower cholesterol.

26 Aug 2011

Psoriasis drug and heart attack risk association unclear: Study

According to American researchers, although a review of published studies reveals that a new and highly effective class of psoriasis drugs does not appear to raise the risk of heart problems, the studies may not have been big enough to detect rare cases.

24 Aug 2011

Trophos awarded US patent covering use of novel cardioprotective compound

Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of their novel mitochondrial pore modulator, TRO40303, for cytoprotection. The patent provides coverage for the use of Trophos’ TRO40303 to reduce the cardiac reperfusion injury that contributes significantly to the morbidity and mortality seen after a heart attack (myocardial infarction - MI).

23 Aug 2011

Faster angioplasty for most heart attack victims: Study

According to a new study more than 90% of patients who have a heart attack and need an emergency treatment like angioplasty now have it within the recommended 90 minutes after they get to the hospital.

23 Aug 2011

Calcium scores and heart disease risk, experts debate

...

22 Aug 2011

Bear bile compound may help treat heart attack: Study

The compound, ursodeoxycholic acid (UDCA), is already used to lower cholesterol and help dissolve gallstones, and it's a key ingredient in many traditional Chinese medicines, which use bear bile. According to the latest research from Imperial College London it might also be able to treat abnormal heart rhythm, or arrhythmia, in fetuses and heart attack victims.

3 Aug 2011

Scientists look to create blood platelets from stem cells to study genetics of blood clotting disorders

Johns Hopkins scientists have launched a pioneering research program to create, for the first time, human platelet cells from stem cells in order to study inherited blood clotting abnormalities ranging from clots that cause heart attacks and stroke to bleeding disorders. The study is funded by a $9 million grant from the National Institutes of Health (NIH) as part of a nationwide initiative to examine how genetic variations cause heart, lung and blood diseases.

2 Aug 2011

Hormone therapy may be hazardous in men with pre-existing heart conditions

Adding hormone therapy to radiation therapy has been proven in randomized clinical trials to improve overall survival for men with intermediate- and high-risk prostate cancer. However, adding hormone therapy may reduce overall survival in men with pre-existing heart conditions, even if they have high-risk prostate cancer according to a new study just published online in advance of print in the International Journal of Radiation Oncology·Biology·Physics, the official scientific journal of ASTRO.

26 Jul 2011

AstraZeneca receives FDA approval for BRILINTA to treat acute coronary syndrome

AstraZeneca announced today that the US Food and Drug Administration (FDA) has approved BRILINTA (ticagrelor) tablets to reduce the rate of heart attack and cardiovascular (CV) death in adult patients with acute coronary syndrome (ACS), compared to clopidogrel.

21 Jul 2011

FDA approves AstraZeneca's anti-clotting drug Brilinta

The U.S. Food and drug Administration (FDA) has finally approved AstraZeneca's Brilinta blood thinner for patients with acute coronary syndrome - conditions, such as heart attack and angina.

20 Jul 2011

Stopping Aspirin may raise heart attack death risk by 60%: Study

The study results revealed that patients with a history of heart disease who stopped taking a low-dose daily aspirin had a 60% increased risk of having a heart attack over the three-year follow-up, compared with patients who continued the daily aspirin, says study researcher Luis A. Garcia Rodriguez, director of the Spanish Center for Pharmacoepidemiologic Research (CEIFE) in Madrid. The study is published in the British Medical Journal.

20 Jul 2011